(Q37922370)

25 August 2017

1 reference

title

The cryoglobulinaemias (English)

1 reference

25 August 2017

Manuel Ramos-Casals

1

0 references

Maria Cinta Cid Xutglà

object named as

Maria C Cid

series ordinal

3

0 references

author name string

John H Stone

series ordinal

2

1 reference

25 August 2017

Xavier Bosch

series ordinal

4

1 reference

25 August 2017

language of work or name

English

0 references

publication date

23 August 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

379

1 reference

25 August 2017

issue

9813

1 reference

25 August 2017

page(s)

348-360

1 reference

25 August 2017

cites work

Mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Studies of cryoglobulins; unusual purpura associated with the presence of a high concentration of cryoglobulin (cold precipitable serum globulin).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Cryoglobulinemia--a study of twenty-nine patients. I. IgG and IgM cryoglobulins and factors affecting cryoprecipitability

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Biologic and clinical significance of cryoglobulins. A report of 86 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Two-dimensional polyacrylamide gel electrophoresis analysis of cryoglobulins and identification of an IgM-associated peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

1 reference

7 January 2021

Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Antibodies to hepatitis C virus in patients with mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Hepatitis C virus infection, cryoglobulinaemia, and beyond.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

1 reference

7 January 2021

Mixed cryoglobulinemia: demographic, clinical, and serologic features and survival in 231 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Mixed cryoglobulinemia in HIV-1 infection: the role of HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Prevalence and clinical significance of circulating cryoglobulins in HIV-positive patients with and without co-infection with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Decreased prevalence of mixed cryoglobulinemia in the HAART era among HIV-positive, HCV-negative patients.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Mixed cryoglobulinemia: new concepts

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Mixed monoclonal cryoglobulinemia and monoclonal rheumatoid factor cross-reactive idiotypes as predictive factors for the development of lymphoma in primary Sjögren's syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Predicting adverse outcomes in primary Sjogren's syndrome: identification of prognostic factors

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Hematologic manifestations and predictors of lymphoma development in primary Sjögren syndrome: clinical and pathophysiologic aspects

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Sjögren syndrome associated with hepatitis C virus: a multicenter analysis of 137 cases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Cryoglobulinemia in systemic lupus erythematosus: Prevalence and clinical characteristics in a series of 122 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Mixed cryoglobulinemia: a model of virus-related disease in internal medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Hematologic malignancies in patients with cryoglobulinemia: Association with autoimmune and chronic viral diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Occult hepatitis C virus infection in type II mixed cryoglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Cryoglobulins are not essential

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Hepatitis C, cryoglobulinemia, and cirrhosis: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Hepatitis C virus, Sjögren's syndrome and B-cell lymphoma: linking infection, autoimmunity and cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Binding of hepatitis C virus to CD81

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Intrahepatic B cell clonal expansions and extrahepatic manifestations of chronic HCV infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Bone marrow B-cell clonal expansion in type II mixed cryoglobulinaemia: association with nephritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Clonal expansion of immunoglobulin M+CD27+ B cells in HCV-associated mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Cross-reacting idiotypes on cryoprecipitating rheumatoid factor

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Hepatitis C virus-related proteins in kidney tissue from hepatitis C virus-infected patients with cryoglobulinemic membranoproliferative glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Non-enveloped HCV core protein as constitutive antigen of cold-precipitable immune complexes in type II mixed cryoglobulinaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Cryoglobulin evaluation: best practice?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Role of galactosylation in the renal pathogenicity of murine immunoglobulin G3 monoclonal cryoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Role of the Receptor for the Globular Domain of C1q Protein in the Pathogenesis of Hepatitis C Virus-Related Cryoglobulin Vascular Damage

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Hyperviscosity syndrome in cryoglobulinemia: clinical aspects and therapeutic considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Mortality rate and outcome factors in mixed cryoglobulinaemia: the impact of hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

How I treat Waldenström macroglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Characteristics and outcome of 49 patients with symptomatic cryoglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Absence of antibodies to cyclic citrullinated peptide in sera of patients with hepatitis C virus infection and cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Fatigue in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Thyroid involvement in patients with overt HCV-related mixed cryoglobulinaemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Natural history and therapy of 66 patients with mixed cryoglobulinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Cryoglobulinemia and renal disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

The clinical and morphologic spectrum of renal cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Long-term predictors of survival in essential mixed cryoglobulinemic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Life-threatening infections following rituximab therapy in renal transplant patients with mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Recurrent essential mixed cryoglobulinemia in renal allografts. Report of two cases and review of the literature

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Cryoglobulinemia is a frequent cause of peripheral neuropathy in undiagnosed referral patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Peripheral neuropathy in hepatitis C virus infection with and without cryoglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Prevalence and characteristics of peripheral neuropathy in hepatitis C virus population

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

[Cryoglobulinemic peripheral neuropathy in hepatitis C virus infection: clinical and anatomical correlations of 22 cases].

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Presentation and outcome of gastrointestinal involvement in hepatitis C virus-related systemic vasculitis: a case-control study from a single-centre cohort of 163 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Interstitial lung fibrosis and rheumatic disorders in patients with hepatitis C virus infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

The nervous system and hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Adequate sampling in cryoglobulinaemia: recommended warmly

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

A critical appraisal of current practice in the detection, analysis, and reporting of cryoglobulins

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

The presence of cryoprecipitable immunoglobulins in normal human sera may reflect specific molecular interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Analysis and general classification of serum cryoglobulins by capillary zone electrophoresis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Hypercomplementaemia as a marker of the evolution from benign to malignant B cell proliferation in patients with type II mixed cryoglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Prevalence of glomerulopathies in autopsies of patients infected with the hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Cryoglobulinemic neuropathy: a pathological study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Life-threatening cryoglobulinemia: clinical and immunological characterization of 29 cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Emergency in cryoglobulinemic syndrome: what to do?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Hepatitis C-associated mixed cryoglobulinaemia: a crossroad between autoimmunity and lymphoproliferation

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Mixed cryoglobulinemia as a possible preneoplastic disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

The role of hepatitis C virus in the aetiology of non-Hodgkins lymphoma--a regional association?

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Incidence and characteristics of non-Hodgkin lymphomas in a multicenter case file of patients with hepatitis C virus-related symptomatic mixed cryoglobulinemias

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Surrogate markers of B cell non-Hodgkin's lymphoma in patients with hepatitis C virus-related cryoglobulinaemia vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Risk of non-Hodgkin lymphoma and lymphoproliferative precursor diseases in US veterans with hepatitis C virus

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Causes of death in symptomatic cryoglobulinemia: 30 years of observation in a Department of Internal Medicine

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Hepatitis C virus infection and vasculitis: implications of antiviral and immunosuppressive therapies

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Mechanism of action of interferon and ribavirin in treatment of hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Diagnosis, management, and treatment of hepatitis C: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Symptomatic and virological response to antiviral therapy in hepatitis C associated with extrahepatic complications of cryoglobulimia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Side effects of therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Acute exacerbation of vasculitis during interferon-alpha therapy for hepatitis C-associated cryoglobulinaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Interferon-alpha may exacerbate cryoblobulinemia-related ischemic manifestations: an adverse effect potentially related to its anti-angiogenic activity

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Safety and antiviral activity of albinterferon alfa-2b in prior interferon nonresponders with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Rituximab treatment for glomerulonephritis in HCV-associated mixed cryoglobulinaemia: efficacy and safety in the absence of steroids

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Rituximab induces remission in refractory HCV associated cryoglobulinaemic vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Efficacy and safety of rituximab in type II mixed cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Restoration of peripheral immune homeostasis after rituximab in mixed cryoglobulinemia vasculitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Long-term effects of anti-CD20 monoclonal antibody treatment of cryoglobulinaemic glomerulonephritis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Relapse of hepatitis C virus-associated mixed cryoglobulinemia vasculitis in patients with sustained viral response.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Rituximab plus Peg-interferon-alpha/ribavirin compared with Peg-interferon-alpha/ribavirin in hepatitis C-related mixed cryoglobulinemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Pegylated interferon-alpha, ribavirin, and rituximab combined therapy of hepatitis C virus-related mixed cryoglobulinemia: a long-term study.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Safety and efficacy of rituximab in patients with hepatitis C virus-related mixed cryoglobulinemia and severe liver disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Safety and efficacy of rituximab in nonviral cryoglobulinemia vasculitis: data from the French Autoimmunity and Rituximab registry

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Rituximab-associated infections

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Rituximab may form a complex with iGmÎº mixed cryoglobulin and induce severe systemic reactions in patients with hepatitis C virusâ induced vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Causes and predictive factors of mortality in a cohort of patients with hepatitis C virus-related cryoglobulinemic vasculitis treated with antiviral therapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Response to bortezomib in refractory type I cryoglobulinemia

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Preliminary classification criteria for the cryoglobulinaemic vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Rituximab monotherapy, rather than rituximab plus antiviral drugs, for initial treatment of severe hepatitis C virus-associated mixed cryoglobulinemia syndrome: comment on the article by Terrier et al.

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

Hepatitis C virus-associated B-cell proliferation--the role of serum B lymphocyte stimulator (BLyS/BAFF).

1 reference

https://api.crossref.org/works/10.1016%2FS0140-6736%2811%2960242-0

7 January 2021

10.1016/S0140-6736(11)60242-0

Identifiers

DOI

1 reference

25 August 2017

1 reference